• Combination immunotherapy for cancer

    Dr. Patrick Reeves supervises graduate student Farah Kools in preparation of samples for a cellular assay.

  • Islet Transplant

    Madeline Penson prepares microencapsulated islets to be used in preclinical therapeutic studies for treatment of diabetes.

  • Wound healing

    Dr. Ruxandra Sîrbulescu analyzes flow cytometry data on immune cells used in a wound healing study.

  • Laser Vaccine Adjuvant

    Dr. Yoshifumi Kimizuka supervises medical student Yusuke Shimaoka in making skin temperature measurements on mice before laser treatment.

The Vaccine and Immunotherapy Center (VIC) at Massachusetts General Hospital seeks to improve human health by accelerating the development of new broadly applicable, safe and cost effective vaccines and immune-based therapeutics. We focus on enhancing the speed and effectiveness by which these drugs and vaccines are advanced from laboratory discovery to clinical development, on promoting an understanding of the need for accelerated development of new medical treatments, and on training the next generation of scientists to continue this important work.

VIC prioritizes for development innovations with the potential for making a broad impact on cancer, infectious diseases, type 1 diabetes and other immune-mediated diseases, as well as the promise of benefitting patients across the globe. We actively manage the development of these candidates, drawing on the expertise and experience of medical and business professionals who collectively understand each aspect of the development path from discovery to the use of new medicines in people.

VIC’s metrics of success are clear: It aims to successfully advance research initiatives efficiently from the preclinical stage to the clinical stage of development and eventually to a point where a successful product can be safely adopted by an industry or a non-profit development partner. Through the support of public grants and private philanthropy, VIC has supported rapid-pace, high-impact research initiatives that are in the process of safely transitioning from the research lab to patients.